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Objective: This review will systematically examine and synthesize the evidence evaluating the effectiveness and
safety of interventions that enable non-allergy specialist health care workers to assess allergy risk in patients with
reported penicillin allergies and subsequently remove erroneous allergy records.
Introduction: The potential benefits of removing erroneous penicillin allergy labels (de-labeling) are wide-ranging.
Penicillin allergy assessment and de-labeling is an antibiotic stewardship priority. Delivery of such assessment and
de-labeling by non-allergy specialists has been reported in several studies, but the effectiveness and safety have not
been formally synthesized. This is a necessary step in the upscaling of penicillin allergy assessment services.
Inclusion criteria: This review will consider quantitative studies using appropriate designs. The studies will include
adults and pediatric patients who have undergone penicillin allergy assessment and de-labeling by non-allergy
specialists in any health care setting.
Methods: A range of databases will be searched to identify studies published in English, with no date limit.
Unpublished studies and gray literature will also be searched. Title and abstract screening, and assessment of
selected full texts against the inclusion criteria will be conducted by at least two independent reviewers. Identified
studies will be assessed for methodological quality using standardized critical appraisal instruments. Data will be
extracted and categorized using the EPOC taxonomy, and the effectiveness and safety of the intervention will
be determined. Where possible, data will be pooled to facilitate meta-analysis. Data from heterogeneous studies will
be reported narratively. The GRADE approach for grading the certainty of evidence will be followed.
Systematic review registration number: PROSPERO CRD42020219044
Keywords: antimicrobial stewardship; penicillin allergy assessment; penicillin allergy de-labeling
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Introduction
A pproximately 6% of the general population inEngland1 and 15% of hospital inpatients in
England and elsewhere2-4 have a record of penicillin
allergy. Penicillin-based antibiotics are first-line
treatment for many common infections; however,
patients with penicillin allergy labels are usually
treated with second-line antibiotics.2 Second-line
antibiotics are often more costly,5-7 less effective
in certain clinical circumstances,1,8-10 and more
toxic.5 Moreover, they are often broader spectrum,
which potentially increases a patient’s risk of future
infections with resistant bacteria.5,11 Patients with
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penicillin allergy records are also associated with
exposure to a greater number of antibiotics,
increased length of hospital stay,2,4 and higher hos-
pital readmission rates,12 all of which increase costs
to health care systems.
However, more than 90% of individuals with a
penicillin allergy label are not allergic to penicillin.13
Assessing patients with penicillin allergy labels to
identify those who are not allergic to penicillin, and
then de-labeling them, has the potential to reduce
second-line antibiotic use in favor of penicillin,
thereby reducing the unintended consequences asso-
ciated with second-line antibiotics.
Penicillin allergy assessment of patients with a
reported penicillin allergy has traditionally been the
domain of allergy experts. Allergy services in the UK
and elsewhere are limited,14 and many hospitals do
not have direct access to such services. Furthermore,
allergy services do not have capacity to assess and
de-label the potentially large number of patients
with reported allergies to penicillin. Traditional
penicillin allergy testing requires skin testing prior
to an oral challenge test, and this is still the main
testing method in UK allergy centers. Therefore,
penicillin allergy testing is resource-intensive. A less
resource-intensive penicillin allergy de-labeling
method uses a direct oral penicillin challenge in
patients with a history consistent with low risk of
future penicillin allergy, forgoing the need for skin
testing.
Direct oral challenge testing makes allergy assess-
ment possible outside allergy centers because it is
quicker and less resource-intensive than the tradi-
tional skin test method. Non-allergy specialist
researchers have explored penicillin allergy assess-
ment and de-labeling of hospitalized patients15,16
and found it to be safe and effective, resulting in
increased use of penicillin antibiotics instead of
second-line antibiotics with minimal evidence of side
effects. Two systematic reviews have confirmed the
safety and efficacy of direct oral challenge delivered
by allergists and non-allergists as a method of de-
labeling adults.17,18 Other methods delivered by
non-allergists, such as skin testing, have also been
successfully delivered in the inpatient and outpatient
settings.19,20
Leading allergists in the US have suggested that
every physician needs to obtain an accurate drug
intolerance history before avoiding a beta-lactam
antibiotic (the broader group name that includes
the penicillin antibiotic group) when it is the drug
of choice. These allergists also postulate that
addressing unconfirmed beta-lactam allergy on a
large scale would lead to a dramatic reduction in
the morbidity and mortality associated with uncon-
firmed beta-lactam allergy and reduce associated
health care costs.21 In September 2020, the Ameri-
can Academy of Allergy, Asthma and Immunology,
together with the Infectious Diseases Society of
America, wrote to the Centers for Medicare and
Medicaid Services to urge US hospitals to include
verification of penicillin allergy as part of its man-
datory antibiotic stewardship programs.22 More
recently, the World Health Organization recom-
mended antibiotic de-labeling as an effective antimi-
crobial stewardship strategy.23 However, knowledge
of the epidemiology of penicillin allergy labels and
their association with antimicrobial resistance in
low- and middle-income countries is sparse, as is
the evidence for established antibiotic de-labeling
pathways,24 with the majority of studies occurring
in high-income countries.
Penicillin allergy de-labeling is supported by
health care workers and accepted by patients. Health
care workers in a UK hospital reported frequently
encountering patients with penicillin allergy records
they believed to be erroneous, and recognized that
incorrect penicillin allergy records were a problem.25
An Australian study demonstrated patient accept-
ability for oral penicillin challenges to rule out
penicillin allergy,26 while a US study found that
patients believed that penicillin allergy testing pro-
vided valuable medical information.27
Enabling the wider health care workforce to
assess patients with penicillin allergy records and
to de-label eligible patients is required to ensure
penicillin allergy assessment and de-labeling at
scale. Lin et al.28 reported on a successful general
physician-delivered penicillin allergy de-labeling
program in hospitalized patients in the Netherlands.
The intervention included physician education,
distributing pocket-sized reminder cards, and
electronic medical records to prompt physicians
to perform the necessary assessment. Maguire
et al.29 reported a successful US emergency depart-
ment physician-delivered, penicillin allergy de-
labeling patient pathway. The intervention included
the development of a penicillin and cephalosporin
test dose procedure guideline, pharmacist-led
education, physician-ordered test doses, pharmacist
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verification, and nurse administration and post-
challenge dose observation.
In this review, we aim to systematically examine
the literature to identify and determine the effective-
ness of interventions that enable non-allergy special-
ist health care workers to assess and, where
appropriate, de-label adult and pediatric patients
with a reported penicillin allergy in any health care
setting. The review will also identify and synthesize
those components of the interventions that make
them safe and effective. A non-allergy specialist is
defined as a medical professional whose primary
specialization is not in allergy or who has not trained
in allergy as part of their specialty.30
A preliminary search of PROSPERO, MEDLINE,
the Cochrane Database of Systematic Reviews, and
JBI Evidence Synthesis was conducted and no cur-
rent systematic reviews on the topic were identified.
However, one systematic review by Cooper et al.17
was underway, synthesizing the evidence on the
safety and efficacy of de-labeling penicillin allergy
in adults using direct oral challenge. This has since
been published, and shows that direct oral challenge
delivered by both allergists and non-allergists, is safe
and effective as a method of de-labeling adults. Our
proposed systematic review will be more focused
than that of Cooper et al.17 because it will look
solely at non-allergists. However, the scope will also
be broader because the review will not be limited by
health care setting. It will also consider children and
adolescents as well as adults, and will include all
methods to de-label patients with incorrect penicillin
allergy labels. We will narrow our search to non-
allergists because we wish to understand the wider
frameworks that enable non-allergists to assess pen-
icillin allergy records and safely de-label patients. If
this issue is to be tackled at scale, we need to mobilize
the non-allergist workforce and teach it how to do
this safely.
The findings of this review will inform the devel-
opment of a complex intervention designed to facili-
tate and embed penicillin allergy assessment and de-
labeling. The intervention will be delivered by non-
allergy specialists as part of a secondary care anti-
microbial stewardship program in a UK hospital.
The objectives of this systematic review are to i)
identify and synthesize the range of interventions
and allergy testing methods used by non-allergists to
assess reported penicillin allergies and subsequent
de-labeling; ii) identify which types of health care
workers have been targeted by interventions to
assess and de-label penicillin allergy records (as
per the first objective); and iii) determine the effec-
tiveness (increased penicillin antibiotic use) and
safety (absence of adverse drug events) of strategies
used to deliver non-allergy specialist inpatient de-
labeling in hospitalized patients.
Review question
What is the effectiveness and safety of interventions
that facilitate non-allergy specialist health care
workers’ assessment of adults and pediatric patients
with reported penicillin allergy, with subsequent de-
labeling of erroneous records?
Inclusion criteria
Participants
This review will include studies with any patient
(adults, adolescents, or children) who have a peni-
cillin allergy record or self-reported allergy to peni-
cillin, upon direct questioning, in any health care
context and from any country.
Interventions
The review will include studies reporting on penicil-
lin allergy de-labeling using any method (direct de-
label, direct oral challenge, skin testing, or oral
challenge) by non-allergy specialists, which include,
but are not limited to, nurses, pharmacists, and
physicians. Penicillin allergy assessment and de-
labeling interventions delivered by immunologists
or allergy specialists will be excluded.
Comparators
The comparators will be adults, adolescents, and
children who receive usual standard care and do
not undergo penicillin allergy assessment. Due to
the nature of the intervention, there may not be a
comparator group; therefore, studies without a com-
parator or control group will not be excluded.
Outcomes
The primary outcomes will be the number of adults,
adolescents, or children with a penicillin allergy
record who are successfully de-labeled. The second-
ary outcomes will be i) any measured antimicrobial
stewardship impact (eg, antibiotic class prescribed,
antibiotic cost, antibiotic side effects, treatment fail-
ure, health care associated infections, antibiotic
resistant infections); ii) any measured health care
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system impact (eg, length of hospital stay, health
care resource utilization); and iii) any unintended
harm associated with the de-labeling process (eg,
anaphylaxis, side effects of antibiotics).
Types of studies
This review will consider both experimental and
quasi-experimental study designs, including random-
ized controlled trials, non-randomized controlled tri-
als, before and after studies, and interrupted time-
series studies. In addition, the review will consider
analytical observational studies, including prospec-
tive and retrospective cohort studies, case-control
studies, analytical cross-sectional studies, and
descriptive observational study designs. Case reports
will be excluded.
Methods
The systematic review will be conducted in accor-
dance with the JBI methodology for systematic
reviews of effectiveness,31 and reported using the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) checklist.32
The protocol has been registered in PROSPERO
(CRD42020219044).
Search strategy
The search strategy will aim to locate both published
and unpublished studies. An initial limited search of
Embase was undertaken to identify articles on the
topic. The text words contained in the titles and
abstracts of relevant articles, and the index terms
used to describe the articles were used to develop a
full search strategy for Embase (Ovid; Appendix I).
The search strategy, including all identified key-
words and index terms, will be adapted for each
included database and/or information source. Back-
wards and forwards reference searches of all
included sources of evidence will be completed to
identify additional studies.
Only studies published in English will be included
due to a lack of funding for translation services. No
date limit will be set for included studies because this
is a relatively new antimicrobial stewardship inter-
vention, and studies are only expected to be identi-
fied from 2010 onwards.
The databases to be searched from their inception
to the present day will include Embase (Ovid),
MEDLINE (Ovid), CINAHL (Ovid), PsycINFO,
Web of Science, and Cochrane CENTRAL. Sources
of unpublished studies/gray literature will include
the World Health Organization Library database,
key organization websites and conference proceed-
ings (eg, European Society of Clinical Microbiology
and Infectious Diseases, Society for Healthcare Epi-
demiology of America, Healthcare Infection Society,
Infection Prevention Society), registered controlled
trial registers, technical or research reports from
government agencies, and the British Library
(EThOS) Collection of PhD dissertations.
We will contact known experts in the topic
regarding any unpublished work and to ensure we
have not overlooked relevant literature.
Study selection
Following the search, all identified citations will be
collated and uploaded into Endnote Note v.X9.2
(Clarivate Analytics, PA, USA) and duplicates
removed. Following a pilot test, titles and abstracts
will then be screened by at least two independent
reviewers for assessment against the inclusion crite-
ria for the review using RAYYAN software (Qatar
Computing Research Institute, Doha, Qatar). Poten-
tially relevant studies will be retrieved in full and
their citation details imported into the JBI System
for the Unified Management, Assessment and
Review of Information (JBI SUMARI; JBI, Adelaide,
Australia).33 The full text of selected citations will be
assessed in detail against the inclusion criteria by at
least two independent reviewers using RAYYAN
software. Reasons for exclusion of papers at full
text that do not meet the inclusion criteria will be
recorded and reported in the systematic review. Any
disagreements that arise between the reviewers at
each stage of the selection process will be resolved
through discussion or with an additional reviewer.
The results of the search and the study inclusion
process will be reported in full and presented in a
PRISMA flow diagram.32
Assessment of methodological quality
Eligible studies will be critically appraised by two
independent reviewers at the study level for meth-
odological quality using standardized critical
appraisal instruments from JBI for experimental,
quasi-experimental, observational, and descriptive
studies.31 Authors of papers will be contacted to
request missing or additional data for clarification,
where required. Any disagreements that arise will be
resolved through discussion or with a third reviewer.
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The results of the critical appraisal will be reported
in narrative format and in a table.
Studies will not be excluded on the grounds of
their risk of bias, but the risk of bias will be reported
when presenting the results. The risk of bias judg-
ments will be summarized across different studies for
each of the domains listed using the risk of bias graph
and the risk of bias summary. Therefore, all studies,
regardless of the results of their methodological
quality, will undergo data extraction and meta-anal-
ysis, where possible.31
Data extraction
Data will be extracted from studies included in the
review by two independent reviewers using the stan-
dardized data extraction tool from JBI.31 The
extracted data will include specific details about
the populations, study methods, interventions, and
outcomes of significance to the review objectives and
interventions. These data will be categorized using
Cochrane’s Effective Practice and Organisation of
Care taxonomy of health interventions.34 Authors of
papers will be contacted to request missing or addi-
tional data, where required.
Data synthesis
Studies will, where possible, be pooled in statistical
meta-analysis using JBI SUMARI.33 Effect sizes will
be expressed as either odds ratios (for dichotomous
data) or weighted (or standardized) final post-inter-
vention mean differences (for continuous data), and
their 95% confidence intervals will be calculated for
analysis. Heterogeneity will be assessed statistically
using the standard x2 and I2 tests, and reasons for
heterogeneity will be explored using subgroup and/
or sensitivity analyses. Subgroups may include the
penicillin allergy de-label method used (eg, direct de-
label, direct oral challenge), the setting (inpatient or
outpatient), or patient age (adults, adolescents, or
children). Statistical analyses will be performed
using the random effects model, or if study numbers
are small, the fixed effects model.35 Where statistical
pooling is not possible, the findings will be presented
in narrative format, including tables and figures, to
aid in data presentation. A funnel plot will be gen-
erated to assess publication bias if there are 10 or
more studies included in a meta-analysis. Statistical
tests for funnel plot asymmetry (Egger test, Begg
test, Harbord test)36-38 will be performed where
appropriate.
Assessing certainty in the findings
The Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach
for grading the certainty of evidence will be fol-
lowed,39 and a Summary of Findings (SoF) will be
created using GRADEpro GDT 2020 (McMaster
University, ON, Canada). The SoF will present the
following information where appropriate: absolute
risks for the treatment and control, estimates of
relative risk, and a ranking of the quality of the
evidence based on the risk of bias, directness, het-
erogeneity, precision, and risk of publication bias of
the review results. The outcomes reported in the SoF
will be the proportion of adults, adolescents, or
children with a penicillin allergy record who have
been successfully de-labeled; any measured antimi-
crobial stewardship impact; any measured health
care system impact; and any unintended harm asso-
ciated with the de-labeling process.
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Appendix I: Search strategy
Embase (Ovid) searched October 16, 2020
1. (penicillin adj2 allerg).tw.
2. (penicillin adj2 hypersensitiv).tw.
3. (penicillin adj2 anaphylaxis).tw.
4. (beta-lactam adj2 allerg).tw.
5. (beta-lactam adj2 hypersensitiv).tw.
6. (beta-lactam adj2 anaphylaxis).tw.
7. (‘‘betalactam’’ adj2 anaphylaxis).tw.
8. (‘‘betalactam’’ adj2 hypersensitiv).tw.
9. (‘‘betalactam’’ adj2 allerg).tw.
10. (‘‘lactam’’ adj2 allerg).tw.
11. (‘‘lactam’’ adj2 hypersensitiv).tw.
12. (‘‘lactam’’ adj2 anaphylaxis).tw.
13. (‘‘antibiotic’’ adj2 anaphylaxis).tw.
14. (‘‘antibiotic’’ adj2 hypersensitiv).tw.
15. (‘‘antibiotic’’ adj2 allerg).tw.
16. (‘‘antimicrobial’’ adj2 allerg).tw.
17. (‘‘antimicrobial’’ adj2 hypersensitiv).tw.
18. (‘‘antimicrobial’’ adj2 anaphylaxis).tw.
19. ‘‘PENICILLIN DERIVATIVE’’/
20. ‘‘DRUG HYPERSENSITIVITY’’/ or ANAPHYLAXIS/
21. 19 and 20
22. ‘‘PENICILLIN ALLERGY’’/
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18or 21 or 22
24. ‘‘clinical decision tool’’.tw.
25. ‘‘clinical decision making’’.tw.
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45. 24 or 25 or 26 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
or 44
46. 23 and 45
No limits set, number of returns 3188.
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